etirinotecan pegol
Trade name: Onzeald
Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough. — Wikipedia
Clinical trial activity
19 trials · 8 clinical orgs · 0 marketing orgs
Earliest trial started Jan 1, 2008 (NCT00598975)
Timeline
Indications
Studied for
- Astrocytoma · Phase 2
- Brain Neoplasms · Phase 2
- Breast Neoplasms · Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Colorectal Neoplasms · Phase 2
- Glioblastoma · Phase 2
- Neoplasm Metastasis · Phase 3
- Neoplasms · Phase 2
- Oligodendroglioma · Phase 2
- Ovarian Neoplasms · Phase 2
- Small Cell Lung Carcinoma · Phase 3
Mechanism of action
- DNA topoisomerase IINHIBITOR
TOP1 inhibitor
Its active metabolite, 7-ethyl-10-hydroxycamptothecin, binds to and stabilizes the topoisomerase I-DNA complex, leading to single- and double-stranded DNA breaks and inhibiting DNA repair.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaNektar Therapeutics ↗
- ChEMBLCHEMBL3039558 ↗
Also known as
- etirinotecan pegol
- etirinotecan pegol
- etirinotecan pegol
- etirinotecan pegol
- nktr 102
- nktr 102
- nktr-102
- nktr-102
- nktr-102
- pegylated irinotecan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06586866 | Phase 2 | Sep 26, 2024 | JenKem Technology Co., Ltd. |
| NCT06581380 | Phase 3 | Sep 16, 2024 | JenKem Technology Co., Ltd. |
| NCT06595186 | Phase 2 | Oct 31, 2022 | JenKem Technology Co., Ltd. |
| NCT05158491 | Phase 1/Phase 2 (Phase 2) | Nov 11, 2021 | Chinese Academy of Medical Sciences, JenKem Technology Co., Ltd. |
| NCT04088604 | Phase 1 | Feb 15, 2019 | Chinese Academy of Medical Sciences, Luye Pharma |
| NCT04366648 | Phase 1 | May 4, 2018 | JenKem Technology Co., Ltd. |
| NCT02915744 | Phase 3 | Nov 1, 2016 | Nektar Therapeutics |
| NCT02312622 | Phase 2 | Jan 1, 2015 | National Cancer Institute (NCI), Stanford University |
| NCT01976143 | Phase 1 | Feb 1, 2014 | Nektar Therapeutics |
| NCT01991678 | Phase 1 | Nov 1, 2013 | Nektar Therapeutics |
| NCT01876446 | Phase 2 | Aug 29, 2013 | National Cancer Institute (NCI), Nektar Therapeutics, State University of New York, Buffalo |
| NCT01773109 | Phase 2 | Jan 1, 2013 | University of Pennsylvania |
| NCT01663012 | Phase 2 | Jul 1, 2012 | Nektar Therapeutics, Stanford University |
| NCT01492101 | Phase 3 | Dec 1, 2011 | Nektar Therapeutics |
| NCT01457118 | Phase 2 | Oct 1, 2011 | Nektar Therapeutics |
| NCT00856375 | Phase 2 | Dec 1, 2008 | Nektar Therapeutics |
| NCT00802945 | Phase 2 | Oct 1, 2008 | Nektar Therapeutics |
| NCT00806156 | Phase 2 | Oct 1, 2008 | Nektar Therapeutics |
| NCT00598975 | Phase 2 | Jan 1, 2008 | Nektar Therapeutics |
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nektar Therapeutics | For profit | 11 | 9 | 3 | 2008 |
| JenKem Technology Co., Ltd. | For profit | 5 | 5 | 3 | 2018 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 0 | 2 | 2019 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2013 |
| Stanford University | Academic/Hospital | 2 | 2 | 1 | 2012 |
| Luye Pharma | For profit | 1 | 1 | 1 | 2019 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2013 |